Jul. 1 at 3:33 AM
$ABBV $BMY $PFE $SLS # 3 The Keytruda patent expiration 2028 is existential as it generated
$31.7B in 2025, which is 49% of Merck's total
$65B revenue and core US patent expiry in 2028 and biosimilars from Celltrion, Samsung Bioepis, and Amgen already in preparation. They have a target of
$70B+ revenue by the mid-2030s, which requires replacing a significant portion of Keytruda's revenue within a decade. GPS could solve this in a specific way: GPS + pembrolizumab combination data across 20 WT1-expressing cancer types would generate new label updates, new clinical indications, and extended physician mind-share for Keytruda as a combination backbone. This would be lifecycle management at plattorm scale, not only revenue addition. ✌️🙏❤️🩹
